TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03413969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CREATION
Description: The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
Study: NCT00921804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD 8529
Description: 40mg oral daily capsule administered as a single dose in the morning for 28 days

Intervention type: DRUG
Group type: OTHER
Intervention: Risperidone
Description: 4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8529
Description: Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to match AZD8529
Description: Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match risperidone
Description: Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match risperidone
Description: Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
Study: NCT04708873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 4x4 min intervals of high intensity treadmill running (80-95% of HRR, RPE 7-10 on Borg's category ratio scale of perceived exertion) interspersed with active recovery (slow jogging or fast walking at 50-70% HRR). HIIT-Resistance exercises 2 sessions per week, RPE 5 (hard) 6-8 RM, 1-3 sets of as many repetitions as possible in 60 seconds, active recovery 20-60 seconds b/w exercises,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Continuous Training
Description: Moderate intensity continuous Aerobic exercises (Stationary cycling for 15-20 min followed by treadmill walking for 15-20 min) at 55-70% 55-70% of HRR, RPE 3-4 on Borg's category ratio scale of perceived exertion. The session will be preceded by 5-7 minute warm-up \&amp; 7-10 min cool-down.
Study: NCT03066531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-based intervention
Study: NCT01856231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity - self-efficacy
Description: Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
Study: NCT02044965

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Antibiotic
Description: 2 mg/kg per day via oral ingestion.
Study: NCT02194621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Flavor option 1
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
Study: NCT02044965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: 2 mg/kg per day via oral ingestion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: 2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: 2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
Study: NCT01837485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactol
Description: The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
Study: NCT02194621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Flavor option 2
Description: Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
Study: NCT01837485

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill was applied 3 times a day for 3 months
Study: NCT02711189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin nasal spray given in dose 80

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02194621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste: Crest Cavity Protection toothpaste
Description: Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
Study: NCT02641548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sock of silicone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heel cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heel cream
Study: NCT01162018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Study: NCT02832882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch RFA
Description: No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tumor puncture RFA
Description: Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
Study: NCT03819335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mySugr app
Description: mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Face-to-face visits
Study: NCT02524704

Intervention type: DEVICE
Intervention: CT scan
Description: Applied only when part of the patient's standard care

Intervention type: DEVICE
Intervention: CT scan
Description: Applied only when part of the patient's standard care
Study: NCT04287049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg PO daily
Study: NCT03447418

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Multiple breath nitrogen washout
Description: Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
Study: NCT02170168

Intervention type: OTHER
Intervention: integrated palliative care program
Description: a standardised care pathway, an educational programme and information to general public, patients and their carers
Study: NCT01222559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co.don chondrosphere®
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
Study: NCT02170168

Intervention type: OTHER
Intervention: integrated palliative care program
Description: a standardised care pathway, an educational programme and information to general public, patients and their carers

Intervention type: OTHER
Intervention: integrated palliative care program
Description: a standardised care pathway, an educational programme and information to general public, patients and their carers
Study: NCT01222559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: co.don chondrosphere®
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
Study: NCT03954964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on disposal of opioids
Description: Current class curriculum including education about pain management with additional education about the disposal of opioids.
Study: NCT03046537

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breath test
Description: Collecting breath test from participants

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breath test
Description: Collecting breath test from participants
Study: NCT03513978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAI Exercises Protocol
Description: Progressive exercises to improve the strength and propioception of the male soccer players.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIFA 11+
Description: Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization.
Study: NCT02035683

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/CT
Description: PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
Study: NCT03175445

Intervention type: OTHER
Intervention: CBCT scan by planmeca promax
Description: software measurement tool of CBCT

Intervention type: OTHER
Intervention: CBCT scan by planmeca promax
Description: software measurement tool of CBCT
Study: NCT00454311

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy of Day 3 Embryo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: · day embryo biopsy
Study: NCT04715386

Intervention type: DRUG
Intervention: StrataXRT
Description: Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
Study: NCT01210885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
Study: NCT02303964

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma
Description: Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
Study: NCT01817049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA-based coach education workshop
Description: A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
Study: NCT01210885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Vaccine
Description: MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
Study: NCT00297986

Intervention type: DEVICE
Intervention: Helmet
Description: Evaluation of different interfaces for NPPV
Study: NCT01817049

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo attention control
Study: NCT02018055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin+Ticagrelor
Description: Aspirin+ Ticagrelor after 1month of standard DAPT (Aspirin+Ticagrelor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin+Clopidogrel
Description: Aspirin+ Clopidogrel after 1month of standard DAPT (Aspirin+Ticagrelor)
Study: NCT00659334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxtran-10 (Combidex)
Description: 2.6 mg/kg
Study: NCT02533388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hwato Electronic Acupuncture Treatment Instrument
Description: Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
Study: NCT01000142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light Touch
Description: Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
Study: NCT01004900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Description: This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost/ Timolol/ Azopt/ Brimonidine
Description: Travoprost (Topical eye drops) administered once daily before sleep
Study: NCT00821990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best supportive care
Description: It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
Study: NCT00890227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique
Description: All level open instrumented posterior spinal fusions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive technique
Description: Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
Study: NCT01188161

Intervention type: DEVICE
Intervention: Rotating Chair
Description: Subjects will be spun in rotating chair
Study: NCT00085722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose Prolotherapy
Description: Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Prolotherapy
Description: 7 mL 9% 'normal' saline and 3mL 1% lidocaine

Intervention type: OTHER
Group type: OTHER
Intervention: At-home physical therapy exercise group
Description: Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
Study: NCT03137095

Intervention type: OTHER
Intervention: Cognitive testing
Description: computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.

Intervention type: OTHER
Intervention: Cognitive testing
Description: computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 \& 5.

Intervention type: OTHER
Intervention: Research Brain MRI
Description: Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
Study: NCT00659334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxtran-10 (Combidex)
Description: 2.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxtran-10 (Combidex)
Description: 2.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxtran-10 (Combidex)
Description: 2.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxtran-10 (Combidex)
Description: 2.6 mg/kg
Study: NCT03137095

Intervention type: OTHER
Intervention: Research Brain MRI
Description: Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.